AF
Therapeutic Areas
Adverum Biotechnologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ixoberogene soroparvovec (Ixo-vec) | Neovascular (Wet) Age-Related Macular Degeneration (wAMD) | Phase 3 |
Leadership Team at Adverum Biotechnologies
LF
Laurent Fischer, M.D.
President and Chief Executive Officer
RC
Romuald Corbau, Ph.D.
Chief Scientific Officer
CF
Carla Fiankan
Senior Vice President, Regulatory Affairs
DH
Dena House
Chief People Officer
HJ
Heikki Jouttijärvi
Senior Vice President, Manufacturing